Glimepiride - Sanofi
Alternative Names: Amarel; Amaril; Amaryl; HOE-490; RonameLatest Information Update: 05 Nov 2023
At a glance
- Originator sanofi-aventis
- Developer Lacer; Sanofi; Shandong Zibo - Xinhua - Chemferm (JV)
- Class Antihyperglycaemics; Small molecules; Sulfonylureas
- Mechanism of Action Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 27 Jul 2022 Lacer has been acquired by Italfarmaco
- 31 Jan 2014 Sanofi completes the phase III RECOMMEND trial in Type-2 diabetes mellitus (combination therapy) in Algeria, Colombia, Egypt, Guatemala, India, Iran, Lebanon, Mexico, Russia, Saudi Arabia, South Africa, Tunisia, Turkey, Ukraine and the United Arab Emirates (NCT01459809)
- 16 Feb 2012 Phase-III clinical trials in Type-2 diabetes mellitus (combination therapy) in Algeria, Colombia, Egypt, India, Iran, Lebanon, Mexico, Russia, Saudi Arabia, South Africa, Tunisia, Turkey, Ukraine and United Arab Emirates (Oral) after February 2012